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Received 4 December 2006; received in revised form 26 April 2007; accepted 14 May 2007; Available online 11 June 2007AbstractObjective: Mitral valve repair is the gold standard to restore mitral valve function and is now known to have good long-term outcome. In order
to help perioperative decision making, we analyzed our collective to find independent risk factors affecting their outcome. Methods: We
retrospectively studied our first 175 consecutive adult patients (mean age: 64  10.4 years; 113 males) who underwent primary mitral valve
repair associated with any other cardiac procedures between January 1986 and December 1998. Risk factors influencing reoperations and late
survival were plotted in a uni- andmultivariate analyses. Results:Operativemortality was 3.4% (6 deaths, 0—22nd postoperative day (POD)). Late
mortality was 9.1% (16 deaths, 3rd—125th POM). Reoperation was required in five patients. Kaplan—Meier actuarial analysis demonstrated a
96  1% 1-year survival, 88  3% 5-year survival and a 69  8% 10-year survival. Freedom from reoperations was 99% at 1 year after repair, 97  2%
after 5 years and 88  6% after 10 years. Multivariate analysis demonstrated that residual NYHA class III and IV (p = 0.001, RR 4.55, 95% CI: 1.85—
14.29), poor preoperative ejection fraction (p = 0.013, RR 1.09, 95% CI: 1.02—1.18), functional MR ( p = 0.018, RR 4.17, 95% CI: 1.32—16.67), and
ischemic MR ( p = 0.049, RR 3.13, 95% CI: 1.01—10.0) were all independent predictors of late death. Persistentmitral regurgitation at seventh POD
(p = 0.005, RR 4.55, 95% CI: 1.56—20.0), age below 60 (p = 0.012, RR 8.7, 95% CI: 2.44—37.8), and absence of prosthetic ring (p = 0.034, RR 4.76,
95% CI: 1.79—33.3) were all independent risk factors for reoperation. Conclusions:Mitral valve repair provides excellent survival. However, long-
term outcome can be negatively influenced by perioperative risk factors. Risk of reoperation is higher in younger patients with a residual mitral
regurgitation and without ring annuloplasty.
# 2007 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
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The concept of correcting mitral regurgitation by
elimination of the leaking site was introduced by Merendino
et al. [1] in 1959 with their technique of posteromedial
annuloplasty. In 1969, Carpentier [2] proposed a standardized
technique of mitral repair which, as a key-principle,
decreases the strain on still diseased subvalvular apparatus.
Large number of studies showed that repair of degenerative
mitral valve regurgitation offers a reduced operative
mortality and a better event-free survival when compared
to mitral valve replacement [3]. This has led to an increased
use of techniques of repair over replacement inmany settings
like rheumatic, infectious, and ischemic mitral valve disease
[4—6]. The 20-year Kaplan—Meier survival rate after repair of
degenerative mitral valve regurgitation was 48% (95% CI: 40—
57%), which is similar to the survival rate for a normal
population with the same age structure [5]. Ten-year survival* Corresponding author. Address: Service de Chirurgie Cardio-Vasculaire,
Centre Hospitalier Universitaire Vaudois, rue du Bugnon 46, CH-1011 Lausanne,
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1010-7940/$ — see front matter # 2007 European Association for Cardio-Thoracic
doi:10.1016/j.ejcts.2007.05.008freedom from redo mitral valve surgery varies from 72% to
90%. Risk factors influencing the early and late outcomes of
patients with mitral valve regurgitation should be assessed to
help perioperative decisionmaking for optimal management.
Excellent long-term outcome is already described by expert
hands, but few data exist to define prognostic parameters
valuable during the perioperative period for long-term
results. Apart from surgical expertise, patient selection
and correct indication for mitral valve repair (MVR) may
significantly influence the long-term results. In this regard,
we planned the present study to identify those variables
which in our experience were associated with an increased
risk of adverse long-term outcome.2. Patients and methods
2.1. Patients’ characteristics
This series included the first 175 consecutive patients
(mean age: 64 years) who underwent MVR in our institution
from January 1986 to December 1998. Any MVR done as a lone
procedureorassociatedwithanyother cardiacprocedureswasSurgery. Published by Elsevier B.V. All rights reserved.
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variables were collected retrospectively from our database
and patients’ records by a single investigator (MAR). Demo-
graphic and operative data are summarized in Table 1.
2.2. Surgical procedures
Operations were performed through median sternotomy,
aorto-bicaval canulation, and the standard technique of
cardiopulmonary bypass with moderate hypothermia (30—
32 8C). Myocardial protection was obtained with anterograde
intermittent crystalloid or cold blood cardioplegia combined
with topical cooling. Intraoperative transesophageal echo-
cardiography was carried out routinely before and after
repair since January 1, 1992.
Mitral valve was exposed through standard left atriotomy.
Valve analysis after Carpentier’s functional classification
showed normal leaflet motion (type I) in 37 patients (21%). A
majority of patients (n = 131, 75%) had posterior leaflet
prolapse with rupture of one or more chordae (type II).
Finally, restricted leaflet motion (type III) was diagnosed
in seven patients (4%). Repair technique was basically
standardized with quandrangular resection of prolapsing
posterior leaflet and annulus plication with 3—0 Prolen suture
without sliding plasty; annuloplasty was carried on with
Carpentier—Edwards ring. An annulovalvuloplasty was
performed in 122 (70%) patients, an annuloplasty alone in
35 (20%) patients, and valvuloplasty without a prosthetic ringTable 1
Preoperative and operative patients data
Age (mean age  SD) 64.0 + 10.4 (range 33—82 years)
Gender
Male 113 (65%)
Female 62 (35%)
NYHA class
I 16 (9%)
II 22 (13%)
III 86 (49%)
IV 51 (29%)
MR grading
II 14 (7.5%)
III 43 (25%)
IV 118 (67.5%)
Cardiac rhythm
Sinus rhythm 123 (71%)
Atrial fibrillation 48 (27%)
Pace maker 2 (1%)
Junctional 2 (1%)
Etiology
Degenerative (myxomatous) 125 (71%)
Functional 16 (9%)
Ischemic 15 (9%)
Post-rheumatic 14 (8%)
Infectious endocarditis 5 (3%)
Types of operation
Annulovalvuloplasty 122 (70%)
Isolated annuloplasty 35 (20%)
Isolated valvuloplasty 18 (10%)
Associated operations
CABG 30 (17%)
Valve 23 (13%)
CABG and valve 4 (2%)in 18 (10%) patients because posterior annulus was found
nondilated during routine valve inspection. In 57 patients
(32%), another cardiac procedure was associated to MVR, 30
(17%) had coronary arterial bypass graft (CABG), 23 (13%) had
a complementary valvular procedure, and 4 (2%) had both
CABG and a valvular operation. In the immediate post-
operative period, all patients were anticoagulated with
moderate IV heparin dosage followed by oral anticoagulation
with acenocoumarol (Novartis, Basel, Switzerland) for 3
months, unless patients had another prosthetic valve or
chronic atrial fibrillation which indicated anticoagulation
indefinitely. Operative events were defined as those
occurring within 30 days after surgery or longer if it was
during the same hospitalization. Quality of the repair was
considered successful when the early transthoracic echo-
cardiography showed only a trivial residual mitral valve
incompetence (MVI) of 0—1/4, acceptable when the echo
score was 2/4, and failed when the score was 3—4/4.
2.3. Follow-up
Data on long-term outcome were obtained by question-
naires addressed one-time to the physician in charge of the
patients (response rate 82%) and by phone interview with all
living patients and family or neighbors in case of death.
Further information about complications was obtained from
hospital reports and death certificates from the Swiss Federal
Office of Civil Status. In the end, 8 among 175 patients were
definitively lost. Follow-up was thus 95.4% complete and
represented 728 patients-years with a mean of 8.7 years and
a range from 2.3 to 18.1 years.
We used the published guidelines for reporting valve-
related morbidity and mortality after cardiac valvular
operation of the STS/AATS [7]. Adverse valvular events
reported were all clearly cardiac, sudden death, or
reoperations due to valve-related complications.
2.4. Statistical analysis
Data analysis was done on an intention-to-treat basis and
was performed using a JMP statistical software package (JMP
v. 5.1) from the SAS Institute Inc. (Cary, NC 27513, USA) on a
Macintosh computer. Continuous variables were provided as
mean  SD and compared with Student’s t-test for para-
metric and Wilcoxon for nonparametric variables. Catego-
rical data were analyzed univariately by x2-test or Fischer’s
exact test. Actuarial survival and freedom from reoperation
were calculated by the Kaplan—Meier method and were
univariately compared using the log-rank statistic. To
identify significant independent risk factors influencing late
mortality, all factors with a significance less than 0.1 were
entered into multivariate analysis. Risk ratio and 95%
confidence intervals were calculated using a Cox propor-
tional hazards model. A p-value of less than 0.05 was then
considered statistically significant.3. Results
Using the classical Kaplan—Meier approach, freedom from
combined early and late deaths and reoperations were
M.-A. Rey Meyer et al. / European Journal of Cardio-thoracic Surgery 32 (2007) 301—307 303
Fig. 1. Event-free survival. Survival freedom from reoperation and all cardiac
events.
Table 2
Late deaths univariate analysis
Late deaths 10 years survival Deaths p-value
Preoperative variables
Age 63.2  10.6 years 70.8  6.7 years 0.006
LVEF 63  12% 58  14% 0.145
Size LA 53  7 mm 53  10 mm 0.972
BMI 24.1  3.27 24.81  3.76 0.413
Body area 17.76  0.18 1.75  0.16 0.841
Older than 60 60  11% 0.034
Younger than 60 94  4%
Male 77  9% 0.405
Female 61  16%
NYHA class III-IV 75  17% 0.67
Others NYHA class 88  7%
Preoperative AF 64  13% 0.721
No preoperative AF 80  6%
Etiology
Degenerative valve disease 85  7% 0.001
Others 38  18%
Ischemic 71  18% 0.08
No ischemic 77  7%
Functional 52  16% 0.001
No functional 75  8%
Rheumatic 58  25% 0.557
No rheumatic 72  9%
Perioperative variables
CEC timing 97.5  30.6 138.0  48.4 <0.001
Aortic clamping time 68.2  20.6 94.2  33.5 <0.001
Operation types
Annulovalvuloplasty 80  8% <0.001
Others 44  19%
Annuloplasty 45  20% 0.003
Others 79  8%
Valvuloplasty 67  27% 0.488
Others 72  8%
Associated operations
CABG 33  25% 0.393
Others 77  7%
Associated valve 47  16% <0.001
Others 75  9%
Postoperative variables
Postoperative AF 69  16% 0.89196  1% at 1-year survival, 86  3% at 5-year survival, and
61  8% at 10-year survival (Fig. 1).
3.1. Early mortality
Six patients (3.4%) died perioperatively from OR time
to 22nd postoperative day (POD). Two deaths were due
to severe cardiogenic shock, one of severe intractable
hemorrhage, one froma non-diagnosed late tamponade, one
massive lung embolism in a Jehovah’s Witness, and one with
multiple organ failure secondary to Pseudomonas aerugi-
nosa pneumonia. Multivariate analysis showed that ischemic
MR and NYHA IV functional status were independent risk
factors for early mortality.
3.2. Late mortality
The overall mortality was 12.6% (22/175). Six patients had
died perioperatively which left 169 patients for long-term
follow-up. There were 16 late deaths (9.1%). Kaplan—Meier
actuarial analysis showed a 96  1% 1-year survival, 88  3%
5-year survival and a 69  8% 10-year survival. Most patients
who died were in NYHA class III and IV and 75% were cardiac-
related deaths with eight terminal ischemic cardiopathies,
two sudden deaths, and two cardiac failures (Fig. 2).
Univariate analysis (Table 2) demonstrated that age older
than 60 years, residual congestive heart failure, ischemic
etiology, lone annuloplasty procedure, valvular-associated
operations, residual MR, longer aortic clamping time, andFig. 2. Actuarial global survival. Survival freedom from early and late deaths.
No PO AF 72  9%
7 POD mitral insufficiency 74  11% 0.072
No 7 POD MI 73  8%
NYHA class II—IV residual 39  20% <0.0001
Others 96  2%
LVEF: left ventricular ejection fraction; LA: left atrium; BMI: body mass index;
AF: atrial fibrillation; CABG: coronary arterial bypass graft; 7 POD: seventh
postoperative day.
Bold = All parameters with p  0.05.longer CPB duration were significantly related to lower
survival rates. Annulovalvuloplasty and degenerative valve
disease were associated with higher survival.
By multivariate analysis, the independent predictors of
decreased long-term survival were residual NYHA class III and
IV, ischemic MR, functional MR and preoperative ejection
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Table 4.
3.3. Predictive factors of reoperation
Freedom from reoperation was 99% at 1 year, 97  2% at
5 years and 88  6% at 10 years. The annual linearized rate
of valve failure is increasing progressively with post-
operative years going by from 0.8% patient-year to 1.6%Table 3
Reoperation univariate analysis
Reoperations No reoperation in 10 years
Preoperative variables
Age 64.4  10.4 years
LVEF 63  13%
LA Size 53  8 mm
BMI 24.1  3.2
Body surface area 1.75  0.18
Older than 60 100  0%
Younger than 60 72  13%
Male 90  9%
Female 100  0%
NYHA class III—IV 96  3%
Others NYHA class 93  4%
Preoperative AF 92  8%
No preoperative AF 85  10%
Etiology
Degenerative valve disease 85  7%
Others 100  0%
Ischemic n.a
No ischemic n.a
Functional n.a
No functional n.a
Rheumatic 100  0%
No rheumatic 87  7%
Perioperative variables
CEC timing (min) 101.4  35.5
Aortic clamping time 70.9  23.7
Operation types
Annulovalvuloplasty 96  4%
Others 88  7%
Annuloplasty 94  5%
Others 87  7%
Valvuloplasty 83  15%
Others 89  6%
Associated operations
CABG 96  4%
No CABG 87  7%
Valve 100  0%
No valve 87  7%
Postoperative variables
7 POD mitral insufficiency 42  30%
Others 93  6%
Postoperative AF 97  3%
No postoperative AF 84  9%
LVEF: left ventricular ejection fraction; LA: left atrium; BMI: body mass index; A
postoperative day; n.a: not applicable.patient-year. There were four valve-related reoperations
from 2 to 95 postoperative months and one heart
transplant for terminal dilated cardiomyopathy with
progressive residual valve regurgitation 24 months after
initial mitral valve repair. The two earliest operations
(second and third POM) were due to technical failure with
leaflet tear and annular suture leakage. The two latest
(52nd and 95th POM) had posterior leaflet rupture and
progressive posterior annulus dilatation due to absence ofReoperation p-value
51.4  4.3 years 0.006
61  8% 0.684
57  4 mm 0.074
25.2  2.3 0.426
1.91  0.15 0.046
0.006
0.101
0.233
0.44
0.207
0.489
99.6  13.4 0.908
61.2  10.5 0.363
0.034
0.983
0.005
0.835
0.455
0.0002
0.576
F: atrial fibrillation; CABG: coronary arterial bypass graft; 7 POD: seventh
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Table 4
Independent risk factors of late death and reoperation at multivariate analysis
Multivariate analysis p-value Risk
ratio
95% confidence
interval
Late deaths
Residual NYHA 0.001 4.55 1.85—14.29
Preoperative EF 0.013 1.09 1.02—1.18
Etiology functional 0.018 4.17 1.32—16.67
Etiology ischemic 0.049 3.13 1.01—10.0
Reoperations
7 POD residual MR 0.005 4.55 1.56—20.0
Age <60 years 0.012 8.7 2.44—37.8
Valvuloplasty (absence of ring) 0.034 4.76 1.79—33.3
EF: ejection fraction; 7 POD MR: seventh postoperative day mitral regurgita-
tion.prosthetic ring implantation. All were degenerative mitral
regurgitation.
Significant factors for reoperation risks are summarized in
Table 3.
By multivariate analysis, the independent predictors of
higher reoperation risks were patients younger than 60-year-
old, the absence of prosthetic ring and the presence of a 7-
day postoperative mitral insufficiency higher than degree I.
(Table 4).4. Discussion
4.1. Long-term outcome
Since the introduction of standardized techniques for
mitral valve reconstruction by Carpentier, Duran and
coworkers [8], mitral valve repair has become the surgical
treatment of choice for mitral regurgitation. Independent
predictors of mortality after any mitral procedures like
ageing, NYHA IV functional class, female sex, diabetes,
coronary artery disease, prior transient ischemic attack, and
renal impairment have been already described [9]. Our
short- and long-term survival results were similar to those
obtained in a recent study [10] with 10-year survival of
68  2%. Our overall mortality was 12.5% in mitral valve
repair for any etiologies; this is quite similar to the results
found in literature varying between 4.5% in Italy and 18% in
Alabama [11,12].
The main finding of this study is the identification of
perioperative factors associated with a suboptimal long-term
outcome, which help perioperative decision making to
improve management in complicated settings. The etiology
of MR plays a major role. We have shown that degenerative
MR is a factor influencing positively late outcome, while
ischemic (IMR) and functional mitral regurgitation (FMR) both
act negatively on long-term prognosis. Ischemic mitral
regurgitation is the second most common cause for mitral
surgery in Western countries with a strong impact on late
survival. In our cases, repair was performed because of
annular dilation, while in patients with altered leaflet motion
the valve had been replaced. IMR remains the subject of
much debate and important insights have been gained only
recently in the underlying pathophysiological mechanisms of
the condition. It has been proved that annular dilation is onlyone of the causes of IMR, while leaflet tethering, papillary
muscle displacement, and ventricular remodeling play major
roles. In a study comparing repair versus replacement, late
mortality was not statistically different with an overall
survival probability of 67  7% at 5 years after repair versus
73  9% after replacement [6]. In fact, in IMR, the long-term
survival is dependent on preoperative left ventricular
conditions and underlying pathophysiologic mechanisms like
preoperative ejection fraction and preoperative pulmonary
hypertension, rather than the choice of operative procedure
[13]. It is noticeable that revascularization alone does not
eliminate the negative long-term effects of even mild IMR
[14].
Functional mitral regurgitation, defined as the failure of
the mitral valve to prevent systolic backward flow in the
absence of significant structural or intrinsic valvular disease,
has been associated in 11 (48%) out of 23 patients with aortic
valve replacement for aortic stenosis. Few papers deal with
this problem. Ruel et al. [15] showed that significant FMR
(>2+), increased aged, decreased ventricular function, and
atrial fibrillation all had independent adverse effects on
mortality. This demonstration pleads for a major part of
increased risk of mortality found in our study with FMR.
Our study also confirms that despite preservation of the
mitral apparatus, left ventricular dysfunction remains a
major cause of poor short-term evolution for older patient
suffering from bad cardiac function represented by low LVEF
or residual functional class III and IV, and lower late survival
by old patient with associated valvular operation or
coronaropathy [16].
4.2. Reoperation
In patients with degenerative mitral valve disease, valve
repair using Carpentier’s technique is the gold standard for
surgical correction of mitral regurgitation and has provided
excellent long-term results. Braunberger et al. [5] recently
reported the very long-term results of valve repair in non-
rheumatic mitral valve insufficiency. In patients with isolated
posterior leaflet prolapse, 10- and 20-year freedom from
reoperation was 98.5% and 96.9%, respectively. In those with
isolated anterior prolapse, it was 86.2% and 86.2%,
respectively. Finally, in bileaflet prolapse, it was 88.1% and
82.6%, respectively. These data confirm the excellent results
of Carpentier’s standard techniques of repair and their
stability over a long period of time. As this study reflects the
beginning of our experience, most repair was done in isolated
posterior prolapse and chordal rupture. Our good results are
comparable with those of Perier et al. [17]. Although repair
durability is good in these patients, some will require late
reoperation for recurrent mitral valve dysfunction. Causes of
failed mitral valve repair may be classified as procedure-
related (suture dehiscence, incomplete initial operation,
rupture of previously shortened chordae) or valve-related
(progressive disease, endocarditis). Numerous studies have
documented a high proportion of procedure-related repair
failure and few like Flameng et al. [18] reported on valve-
related linearized rate of failure. These authors showed that
only 50% of patients remain free frommore than trivial mitral
incompetence at 7 years after repair. Their linearized
recurrence rate of regurgitation >1/4 of 6.9% per year and
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our rate of recurrence >2/4 of 1.6% per year. These findings
strongly suggest a progression of the degenerative process
with time. This is not surprising because myxoid changes are
not entirely acquired but also genetically determined.
Pathophysiological findings like glycosaminoglycans content
of valve cells may help to explain why a progressive incidence
of MR is found after initial adequate repair [19].
Residual regurgitation at intraoperative echocardiogra-
phy has been identified by Mohty et al. [10] as an important
factor associated with significantly increased risk of
reoperation. In the present study, we found that residual
regurgitation larger than grade 1/4 at routine postoperative
TTE, absence of prosthetic ring insertion during the
procedure and age younger than 60 years old were all
independent predictors of late redo mitral valve surgery.
Albeit, all patients who needed a reoperation had a
degenerative etiology, this factor was not an independent
predictor in our multivariate analysis. In the beginning of
our experiment we did not check repair with perioperative
ETO, and only failure were given in postoperative echo-
cardiographic investigations. Since 1992, routine use of
perioperative ETO helped the surgeon to select patients for
mitral valve repair and gave immediate checking for quality
of repair. Anterior leaflet prolapse was recognized in
Carpentier series as an independent risk for reoperation.
As this study reflects our early experience in MVR, operators
were very cautious in selecting patients for valve repair. We
used the somewhat pragmatic definition by Fasol and
Mahdjoobian [20] which is based on gross appearance of
the valve. Though we made an attempt to define the
different forms of degenerative valve disease, mainly
Barlow disease and fibroelastic deficiency. As we performed
repair only if degenerative process involved less than 50% of
leaflets (50% rule of thumb), we had only anecdoctical
anterior leaflets repair avoiding statistical analysis of this
subgroup.
Gerbode’ valvuloplasty without annulus reinforcement by
a prosthetic ring is also a marker of reoperation. Our choice
was given to the Carpentier ring, but tight anchorage of any
type of annulus reinforcement prevented a high rate ofmitral
regurgitation progression and subsequent need for reopera-
tion as described in a recent German study [21].
In our collective, all reoperated patients suffered from
degenerative mitral regurgitation, all had trivial to accep-
table residual MR at 7 days postoperative echocardiographic
control, and all were younger than 60 years at first operation
time.
Even if to our knowledge no reoperated patient had
Marfan syndrome or trait of fibro-elastic deficiency, we can
not exclude, due to the statistically higher reoperation rate
by younger patients seen in our multivariate analysis, that a
hereditary disease predisposed them to progression of the
regurgitation after surgery because of the bad ‘quality’ of
their tissues [22].
4.3. Limitation of the study
The major limitation of the present study is that most
information was collected retrospectively, a process that
may reduce the validity of some data. However, particularattention was paid to the methods used in the follow-up
by thorough examination of hospital files and precising
questionnaires with a doubled interview with physicians.
Special emphasis was brought to define accurately the cause
of late death, because most of the deceased patients had no
necropsy [23]. Statistical power, when analysing covariates
in certain subgroups such as endocarditis, was low because
of small numbers of patients and events. Furthermore, the
findings of this study, as with any observational cohort, may
not necessarily be generalizable to all patients with mitral
valve repair.5. Conclusion
Perioperative management of patients undergoing mitral
valve repair could be enhanced by accumulation of specific
knowledge. Mitral valve repair has many advantages and
improves the outcome of surgery for mitral regurgitation.
However, older age, ischemic and functional origin of MR,
supplementary valvular operation, and bad ventricular
function (NYHA IV or low EF) were found to be independent
risk factors of worse evolution for those patients. Reopera-
tions rates were influenced badly by younger age at
operation, persistent significative mitral regurgitation
(2+), and the absence of prosthetic ring implantation.
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